May James M, Qu Zhi-Chao
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.
Biofactors. 2015 Sep-Oct;41(5):330-8. doi: 10.1002/biof.1227. Epub 2015 Sep 4.
Microvascular pericytes take up ascorbic acid on the ascorbate transporter SVCT2. Intracellular ascorbate then protects the cells against apoptosis induced by culture at diabetic glucose concentrations. To investigate whether pericytes might also provide ascorbate to the underlying endothelial cells, we studied ascorbate efflux from human pericytes. When loaded with ascorbate to intracellular concentrations of 0.8-1.0 mM, almost two-thirds of intracellular ascorbate effluxed from the cells over 2 H. This efflux was opposed by ascorbate re-uptake from the medium, since preventing re-uptake by destroying extracellular ascorbate with ascorbate oxidase increased ascorbate loss even further. Ascorbate re-uptake occurred on the SVCT2, since its blockade by replacing medium sodium with choline, by the SVCT2 inhibitor sulfinpyrazone, or by extracellular ascorbate accelerated ascorbate loss from the cells. This was supported by finding that net efflux of radiolabeled ascorbate was increased by unlabeled extracellular ascorbate with a half-maximal effect in the range of the high affinity Km of the SVCT2. Intracellular ascorbate did not inhibit its efflux. To assess the mechanism of ascorbate efflux, known inhibitors of volume-regulated anion channels (VRACs) were tested. These potently inhibited ascorbate transport into cells on the SVCT2, but not its efflux. An exception was the anion transport inhibitor DIDS, which, despite inhibition of ascorbate uptake, also inhibited net efflux at 25-50 µM. These results suggest that ascorbate efflux from vascular pericytes occurs on a DIDS-inhibitable transporter or channel different from VRACs. Further, ascorbate efflux is opposed by re-uptake of ascorbate on the SVCT2, providing a potential regulatory mechanism.
微血管周细胞通过抗坏血酸转运体SVCT2摄取抗坏血酸。细胞内的抗坏血酸随后保护细胞免受糖尿病葡萄糖浓度培养诱导的细胞凋亡。为了研究周细胞是否也可能为下层的内皮细胞提供抗坏血酸,我们研究了人周细胞中抗坏血酸的流出情况。当细胞内抗坏血酸加载到0.8 - 1.0 mM的浓度时,在2小时内几乎三分之二的细胞内抗坏血酸从细胞中流出。这种流出受到培养基中抗坏血酸重新摄取的阻碍,因为用抗坏血酸氧化酶破坏细胞外抗坏血酸来阻止重新摄取会进一步增加抗坏血酸的损失。抗坏血酸的重新摄取发生在SVCT2上,因为用胆碱替代培养基中的钠、使用SVCT2抑制剂磺吡酮或细胞外抗坏血酸对其进行阻断都会加速细胞内抗坏血酸的流失。这一点得到了以下发现的支持:未标记的细胞外抗坏血酸会增加放射性标记抗坏血酸的净流出,在SVCT2的高亲和力Km范围内具有半数最大效应。细胞内抗坏血酸不会抑制其流出。为了评估抗坏血酸流出的机制,我们测试了已知的容积调节性阴离子通道(VRACs)抑制剂。这些抑制剂强烈抑制抗坏血酸通过SVCT2转运进入细胞,但不抑制其流出。阴离子转运抑制剂DIDS是个例外,尽管它抑制抗坏血酸的摄取,但在25 - 50 μM时也抑制净流出。这些结果表明,血管周细胞中抗坏血酸的流出发生在一种不同于VRACs且可被DIDS抑制的转运体或通道上。此外,抗坏血酸的流出受到SVCT2上抗坏血酸重新摄取的阻碍,这提供了一种潜在的调节机制。